CClinicalTrials.gg
Active, not recruitingNCT04201717Updated May 7, 2025Results posted

Intracorporeal Anastomosis Versus Extracorporeal Anastomosis for Left Colon Cancer

An interventional study of laparoscopic assisted left colectomy (extracorporeal anastomosis group) and total laparoscopic left colectomy (intracorporeal anastomosis group) in Colon Cancer, sponsored by Jilin University. Active, not recruiting at 12 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-07.

Sponsored by Jilin University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study aims to investigate the effects of intracorporeal anastomosis and extracorporeal anastomosis in laparoscopic-assisted radical left hemicolectomy on surgical site infection. Also consider perioperative recovery, safety, and oncology outcomes.

Read the detailed description

This is a prospective, randomized controlled trial. In this trial, cases in the intracorporeal anastomosis group and the extracorporeal anastomosis group are allocated at a 1:1 ratio among patients undergoing laparoscopic radical left hemicolectomy. The peri-operative recovery data, complications, oncology outcomes, and survival are compared.

02

Conditions studied

  • Colon Cancer

Browse trials for

Keywords

  • total laparoscopic
  • laparoscopic assisted
  • intracorporeal anastomosis
  • extracorporeal anastomosis
03

In context

Colonic Neoplasms

1,432 studies on the registry are indexed under Colonic Neoplasms; 357 are open to participants now.

This study's enrollment of 350 is above the median of 90 across 1,034 interventional studies indexed under Colonic Neoplasms.

Browse Colonic Neoplasms studies →

Lead sponsor

Jilin University is the lead sponsor of 26 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. age between 18 and 80 years;
  2. histologically or cytologically confirmed left-sided colon cancer (distal transverse colon, left colic flexure, descending colon, or proximal sigmoid colon);
  3. clinical stage T1-4a, N0-2, and M0;
  4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;
  5. suitable for laparoscopic colectomy;
  6. no previous systemic chemotherapy or radiotherapy;
  7. willing to provide written informed consent and comply with the research procedures.

Exclusion criteria

Exclusion criteria

  1. Have a history of malignant colorectal tumor or have metastatic or multiple carcinoma.
  2. Patients with intestinal obstruction, intestinal perforation, intestinal bleeding, etc. who need emergency surgery.
  3. Patients who need to undergo combined organ resection or robot-assisted colectomy.
  4. Patients who are receiving preoperative neoadjuvant therapy.
  5. ASA grade ≥ IV and/or ECOG performance status score > 2.
  6. Cardiopulmonary dysfunction (NYHA cardiac function classification II-IV), liver dysfunction (MELD score greater than 12), or kidney dysfunction (serum creatinine above the upper limit of normal);
  7. Patients with severe psychiatric illness.
  8. Pregnant or lactating women.
  9. Patients who have a history of taking hormonal drugs.
  10. Diabetic patients whose blood sugar cannot be controlled to be within 6.1 - 8.3 mmol/L.
  11. Patients with other clinical and laboratory conditions that are considered by researchers as inappropriate for participating in this trial.

Exit criteria

  1. Patients with other non-tumor diseases that prevent them from continuing to receive this treatment regimen.
  2. Patients who need emergency surgical resection due to intestinal obstruction, intestinal perforation, intestinal bleeding, etc. after being enrolled in the study.
  3. Patients with distant metastasis confirmed by intraoperative exploration or postoperative pathology, including liver, pelvic cavity, ovary, peritoneum, distant lymph node metastasis, etc.
  4. Patients who need combined organ resection as determined by intraoperative exploration.
  5. Patients who request to withdraw from this study cohort for various reasons after being enrolled in the study, or who cannot complete the study plan and follow-up for various reasons.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
350 participants (actual)

Study arms

  • Active comparator
    laparoscopic assisted left colectomy (extracorporeal anastomosis group)

    All patients underwent laparoscopic dissection according to the left hemicolon cancer resection standard. lymph nodes and blood vessels, are completely trimmed and resected in an en bloc fashion. A small incision is made in the middle of the abdomen to trim the mesentery, remove the specimen, and complete the anastomosis. After completing the anastomosis, the incision will be sutured.

    Procedure: laparoscopic assisted left colectomy (extracorporeal anastomosis group)

  • Experimental
    total laparoscopic left colectomy (intracorporeal anastomosis group)

    All patients underwent laparoscopic dissection according to the left hemicolon cancer resection standard. lymph nodes and blood vessels, are completely trimmed and resected in an en bloc fashion. Mesentery resection is performed under laparoscopy, and anastomosis is completed under laparoscopy. A small incision is made to extract the specimen after the anastomosis is completed.

    Procedure: total laparoscopic left colectomy (intracorporeal anastomosis group)

Interventions

  • Procedurelaparoscopic assisted left colectomy (extracorporeal anastomosis group)

    For patients in the control group, the surgeon uses wound edge protectors to exteriorize the colon through a small incision in the midline of the abdomen. A ruler and methylene blue solution are employed to mark the area for colon resection. This guarantees a 10-cm margin from the tumor. Guided by these markers, the marginal vessels and mesentery are divided outside the body. The method of anastomosis is at the surgeon's discretion. A side-to-side anastomosis (including antiperistaltic, isoperistaltic, or overlapping anastomosis) is recommended. Side-to-end or end-to-end anastomosis (sewn by hand or by inserting a circular stapler through the anus or proximal colon) is also allowed. After completing the anastomosis, the incision is sutured. An abdominal drainage tube is inserted at the end of the operation.

  • Proceduretotal laparoscopic left colectomy (intracorporeal anastomosis group)

    In the experimental group, the surgeon will use a 10-cm medical suture and methylene blue solution to mark the resection margin. The marginal vessels and mesentery will be divided inside the body. The proximal and distal colons are resected using a 60mm linear laparoscopic stapler. Side-to-side intracorporeal anastomotic techniques like anti-peristaltic, iso-peristaltic, or overlap methods will be applied. Once the anastomosis is completed, the specimen is retrieved. The surgeon can place the specimen in a sterile plastic bag for retrieval. Alternatively, the surgeon can use a disposable incision retraction fixator to protect the wound. An abdominal drainage tube is inserted.

06

What researchers measure

Primary outcomes

  1. The Count of Participants With Surgical Site Infection (SSI)

    The primary outcome was the incidence of SSI based on the Definitions of CDC guidelines: superficial incisional, deep incisional, and organ/space infections . Infections involving both organ/space and the incisional site (superficial or deep) were categorized as organ/space infections. Surgeons and nurses assessed the presence of infection daily during hospitalization. After hospital discharge, all patients were followed up until 30 days after surgery at outpatient clinics to check the wound.

    Time frame: one month after surgery

Secondary outcomes

  1. the Blood Loss

    It is defined as the blood loss during operation and is measured in milliliters.

    Time frame: one hour after surgery

  2. the Operating Time

    It is defined as the period from cutting the skin to suturing the skin or doing enterostomy. It is measured in minutes

    Time frame: one hour after surgery

  3. the Incidence of Complications

    It includes fever of unknown origin, bowel obstruction, anastomotic leakage, SSI, other incisional complications, respiratory complications, urinary complications, cardiovascular and cerebrovascular complications, diarrhea, chylous fistula, intraperitoneal hemorrhage, digestive hemorrhage, gastroparesis, and others (including bacteremia, cholecystitis, ion discharge, pancreatitis, and mental and behavioral abnormalities). Complications are graded according to the Clavien-Dindo classification.

    Time frame: one month after surgery

  4. The Rate of Conversion to Open Surgery

    It is defined as an abdominal incision larger than that necessary for specimen extraction.

    Time frame: one hour after surgery

  5. Completeness of Specimens

    It is evaluated according to the West classification. The resected specimens will be classified into three groups according to the plane of dissection: mesocolic plane, intramesocolic plane, and muscularis propria plane.

    Time frame: one hour after surgery

  6. Number of Lymph Nodes Dissected

    The number of lymph nodes in the mesentery will be calculated. Additionally, the metastatic lymph nodes will be counted.

    Time frame: one week after surgery

  7. First Defecation Time

    time to first defecate, measured in days.

    Time frame: one week after surgery

  8. the Incision Length

    The incision length is measured with an aseptic ruler at the end of the surgery, after the incision is sutured. It is measured in millimeters.

    Time frame: one hour after surgery

  9. Visual Analogue Scale/Score (VAS)

    Pain severity was assessed 48 hours after the operation using a ruler about 10 cm long. The ruler is numbered from 0 to 10. 0-3 points indicate no to mild pain. 4-6 points represent moderate pain. 7-10 points stand for severe pain.

    Time frame: 2 days after surgery

  10. 3-year DFS (Disease-free Survival)

    DFS was defined as the time from randomization until the discovery of local recurrence, distant metastasis, or death from the tumor.

    Time frame: three years after the operation

  11. 5-year OS (Overall Survival)

    OS was defined as the time from randomization to death due to any cause.

    Time frame: five years after the operation

  12. First Time for Fluid Diet

    time to start food intake, measured in days

    Time frame: one week after surgery

  13. Postoperative Hospital Stay

    The length of hospital stay after surgery.

    Time frame: one month after surgery

07

Results

Posted Feb 26, 2025

Participant flow

Participant flow — Overall Study
MilestoneLaparoscopic Assisted Left Colectomy (Extracorporeal Anastomosis Group)Total Laparoscopic Left Colectomy (Intracorporeal Anastomosis Group)
Started175175
Completed159157
Not completed1618

Outcome measures

PrimaryThe Count of Participants With Surgical Site Infection (SSI)

The primary outcome was the incidence of SSI based on the Definitions of CDC guidelines: superficial incisional, deep incisional, and organ/space infections . Infections involving both organ/space and the incisional site (superficial or deep) were categorized as organ/space infections. Surgeons and nurses assessed the presence of infection daily during hospitalization. After hospital discharge, all patients were followed up until 30 days after surgery at outpatient clinics to check the wound.

Time frame:
one month after surgery
Reported as:
Count of participants · Participants
The Count of Participants With Surgical Site Infection (SSI)
ParticipantsTotal Laparoscopic Left Colectomy (Intracorporeal Anastomosis Group)Laparoscopic Assisted Left Colectomy (Extracorporeal Anastomosis Group)
The Count of Participants With Surgical Site Infection (SSI)1520
Secondarythe Blood Loss

It is defined as the blood loss during operation and is measured in milliliters.

Time frame:
one hour after surgery
Reported as:
Median · ml
the Blood Loss
mlTotal Laparoscopic Left Colectomy (Intracorporeal Anastomosis Group)Laparoscopic Assisted Left Colectomy (Extracorporeal Anastomosis Group)
the Blood Loss50 (10 to 50)50 (10 to 50)
Secondarythe Operating Time

It is defined as the period from cutting the skin to suturing the skin or doing enterostomy. It is measured in minutes

Time frame:
one hour after surgery

Results for this outcome have not been posted.

Secondarythe Incidence of Complications

It includes fever of unknown origin, bowel obstruction, anastomotic leakage, SSI, other incisional complications, respiratory complications, urinary complications, cardiovascular and cerebrovascular complications, diarrhea, chylous fistula, intraperitoneal hemorrhage, digestive hemorrhage, gastroparesis, and others (including bacteremia, cholecystitis, ion discharge, pancreatitis, and mental and behavioral abnormalities). Complications are graded according to the Clavien-Dindo classification.

Time frame:
one month after surgery

Results for this outcome have not been posted.

SecondaryThe Rate of Conversion to Open Surgery

It is defined as an abdominal incision larger than that necessary for specimen extraction.

Time frame:
one hour after surgery

Results for this outcome have not been posted.

SecondaryCompleteness of Specimens

It is evaluated according to the West classification. The resected specimens will be classified into three groups according to the plane of dissection: mesocolic plane, intramesocolic plane, and muscularis propria plane.

Time frame:
one hour after surgery

Results for this outcome have not been posted.

SecondaryNumber of Lymph Nodes Dissected

The number of lymph nodes in the mesentery will be calculated. Additionally, the metastatic lymph nodes will be counted.

Time frame:
one week after surgery

Results for this outcome have not been posted.

SecondaryFirst Defecation Time

time to first defecate, measured in days.

Time frame:
one week after surgery

Results for this outcome have not been posted.

Secondarythe Incision Length

The incision length is measured with an aseptic ruler at the end of the surgery, after the incision is sutured. It is measured in millimeters.

Time frame:
one hour after surgery

Results for this outcome have not been posted.

SecondaryVisual Analogue Scale/Score (VAS)

Pain severity was assessed 48 hours after the operation using a ruler about 10 cm long. The ruler is numbered from 0 to 10. 0-3 points indicate no to mild pain. 4-6 points represent moderate pain. 7-10 points stand for severe pain.

Time frame:
2 days after surgery

Results for this outcome have not been posted.

Secondary3-year DFS (Disease-free Survival)

DFS was defined as the time from randomization until the discovery of local recurrence, distant metastasis, or death from the tumor.

Time frame:
three years after the operation

Results for this outcome have not been posted.

Secondary5-year OS (Overall Survival)

OS was defined as the time from randomization to death due to any cause.

Time frame:
five years after the operation

Results for this outcome have not been posted.

SecondaryFirst Time for Fluid Diet

time to start food intake, measured in days

Time frame:
one week after surgery

Results for this outcome have not been posted.

SecondaryPostoperative Hospital Stay

The length of hospital stay after surgery.

Time frame:
one month after surgery

Results for this outcome have not been posted.

Adverse events

Collected over 30 days after operation. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Total Laparoscopic Left Colectomy (Intracorporeal Anastomosis Group)0/157 (0%)10/157 (6.4%)13/157 (8.3%)
Laparoscopic Assisted Left Colectomy (Extracorporeal Anastomosis Group)0/159 (0%)6/159 (3.8%)24/159 (15.1%)
Most frequent serious events
Most frequent serious events
EventTotal Laparoscopic Left Colectomy (Intracorporeal Anastomosis Group)Laparoscopic Assisted Left Colectomy (Extracorporeal Anastomosis Group)
Clavien-Dindo grade III or higher complicationsSurgical and medical procedures10/1576/159
Most frequent other events
Most frequent other events
EventTotal Laparoscopic Left Colectomy (Intracorporeal Anastomosis Group)Laparoscopic Assisted Left Colectomy (Extracorporeal Anastomosis Group)
Clavien-Dindo graded I-II complicationsSurgical and medical procedures13/15724/159

Baseline characteristics

Age, Continuous
Age, Continuous(years)Total Laparoscopic Left Colectomy (Intracorporeal Anastomosis Group)Laparoscopic Assisted Left Colectomy (Extracorporeal Anastomosis Group)Total
Median62 (55 to 68)61 (53 to 69)61 (54 to 69)
Sex: Female, Male
Sex: Female, Male(Participants)Total Laparoscopic Left Colectomy (Intracorporeal Anastomosis Group)Laparoscopic Assisted Left Colectomy (Extracorporeal Anastomosis Group)Total
Female455297
Male112107219
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Total Laparoscopic Left Colectomy (Intracorporeal Anastomosis Group)Laparoscopic Assisted Left Colectomy (Extracorporeal Anastomosis Group)Total
Asian157159316
bmi
bmi(kg/m^2)Total Laparoscopic Left Colectomy (Intracorporeal Anastomosis Group)Laparoscopic Assisted Left Colectomy (Extracorporeal Anastomosis Group)Total
Median24.5 (22.1 to 26.5)24.8 (22.9 to 27.1)24.6 (22.4 to 26.6)
08

Study locations

12 sites
  • the First Hospital of Jilin University
    Changchun, Ji Lin 130021, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, China
  • Cancer Hospital, Chinese Academy of Medical Sciences
    Beijing, China
  • Chinese People's Liberation Army General Hospital
    Beijing, China
  • Peking Union Medical College Hospital
    Beijing, China
  • Peking University Cancer Hospital
    Beijing, China
  • The Third Hospital of Jilin University (China - Japan Union Hospital of Jilin University)
    Chang chun, China
  • Daping Hospital of Army Medical University
    Chongqing, China
  • Nanfang Hospital of Southern Medical University
    Guangzhou, China
  • Fudan University Shanghai Cancer Center (Cancer Hospital Affiliated to Fudan University)
    Shanghai, China
  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University
    Shanghai, China
  • Shengjing Hospital Affiliated to China Medical University
    Shenyang, China
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Dec 5, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — If other researchers want to get the individual participant data of this study and have proper reasons, we'll share the data after the study is completed. Researchers can send an email to the Principal Investigator to ask for permission to use the data.

Supporting information: Study protocol, Sap, Icf, Analytic code

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04201717
Lead sponsor
Jilin University
Responsible party
Dong Yang (Assisted Investigator, Jilin University) — Principal investigator
First posted
Dec 17, 2019
Start date
Jan 27, 2021
Primary completion
Jul 3, 2024
Completion
Jul 3, 2029 (estimated)
Results posted
Feb 26, 2025
Last update
May 7, 2025

Study contacts

Quan Wang, doctor
principal investigator · The First Hospital of Jilin University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion